PRAX-628

Praxis Precision Medicines · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	PRAX-628
Sponsor	Praxis Precision Medicines
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) (PHASE2, PHASE3)
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures (PHASE2)
A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PRAX-628 CI brief — competitive landscape report
PRAX-628 updates RSS · CI watch RSS
Praxis Precision Medicines portfolio CI